Teduglutide purity certified reference material (GBW09342) developed with 85.0% purity for pharmaceutical quality control
Background
Short bowel syndrome (SBS) is a severe intestinal disorder and a leading cause of chronic intestinal failure, often necessitating parenteral nutrition. Teduglutide, a 33-amino-acid glucagon-like peptide-2 (GLP-2) analog, offers a therapeutic option by promoting intestinal adaptation and reducing dependence on parenteral support. However, ensuring the quality, consistency, and clinical safety of peptide pharmaceuticals like teduglutide requires highly accurate and reliable methods for purity assessment. The absence of a robust certified reference material (CRM) has been a critical gap in establishing standardized analytical methods for this vital drug.
Study Design
Researchers developed a Teduglutide purity certified reference material (CRM), designated GBW09342, using a recombinant gene expression technique for peptide production. The study involved comprehensive purity verification and structural confirmation of the synthesized teduglutide. For CRM certification, two independent isotope dilution mass spectrometry (IDMS) strategies were employed: one based on amino acid (AA) measurements and another, novel approach, based on sulfur measurements. The sulfur-based IDMS strategy was utilized for the first time to certify a solid purity CRM. Additionally, the team assessed the CRM's homogeneity and stability under various storage conditions.
Results
The newly developed Teduglutide purity certified reference material (GBW09342) achieved a certified purity value of 85.0% with an expanded uncertainty of ± 2.7%. This certification was rigorously established through the application of two distinct IDMS methodologies, confirming the robustness of the purity assessment. The CRM demonstrated excellent homogeneity, ensuring consistent quality across the material. Furthermore, stability testing revealed satisfying results under various conditions: > The Teduglutide purity CRM maintained its integrity for at least 14 days when stored at 4 °C, for 24 h at 25 °C, and for an extended period of 12 months when stored at -20 °C. These stability profiles are crucial for practical application and storage of the reference material, ensuring its long-term utility in quality control.
Key Findings
- Teduglutide purity certified reference material (GBW09342) was developed.
- Certified purity value of 85.0% ± 2.7% was established.
- Two independent
IDMSstrategies (amino acid-based and sulfur-based) were used for certification. - The CRM exhibited good homogeneity and satisfying stability for 14 days at 4 °C, 24 h at 25 °C, and 12 months at -20 °C.
- Sulfur-based
IDMSwas used for the first time to certify a solid purity CRM.
Why It Matters
The development of this Teduglutide purity CRM (GBW09342) is a significant step forward for the pharmaceutical industry and for patients relying on this critical medication. It enables the establishment of accurate and reliable analytical methods for purity assessment, directly impacting the quality, consistency, and clinical safety of teduglutide pharmaceutical products. For peptide users and biohackers, this means greater confidence in the purity and potency of teduglutide, as manufacturers will have a gold standard for quality control. This CRM provides a foundational reference for validating analytical methods, ensuring that the active pharmaceutical ingredient (API) meets stringent quality requirements. Moreover, this pioneering use of sulfur-based IDMS for solid purity CRM certification sets a precedent, offering a reliable methodology that can be adapted for the quality control of other peptide-related drugs, potentially improving the overall landscape of peptide drug development and regulation.
teduglutide
short-bowel-syndrome
quality-control
analytical-chemistry
reference-material
peptide-purity